• Connect with us
  • Information
    • About Us
    • Contact Us
    • Careers
    • Partnerships
    • Advertise With Us
    • Authors
    • Browse Topics
    • Events
    • Disclaimer
    • Privacy Policy
  • Australia
    North America
    World
Login
Investing News NetworkYour trusted source for investing success
  • North America
    Australia
    World
  • My INN
Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
  • Reports & Guides
    • Market Outlook Reports
    • Investing Guides
  • Button
Resource
  • Precious Metals
  • Battery Metals
  • Base Metals
  • Energy
  • Critical Minerals
Tech
Life Science
Biotech Market
Biotech News
Biotech Stocks
  • Biotech Market
  • Biotech News
  • Biotech Stocks

Fulgent Genetics to Present at the 25th Annual Credit Suisse Healthcare Conference

Written by Chelsea Pratt
|
Oct. 25, 2016 06:34AM PST

Fulgent Genetics today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference.

Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that Ming Hsieh, its Chairman and Chief Executive Officer, Dr. Harry Gao, its Chief Science Officer, and Paul Kim, its Chief Financial Officer, are scheduled to present at the 25th Annual Credit Suisse Healthcare Conference at the Phoenician hotel in Scottsdale, Arizona on Monday, November 7, 2016 at 4:00 PM MST (3:00 PM PST).

The live audio webcast and accompanying slide presentation can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com, and an audio replay of the webcast will remain available on the company’s website through December 7, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Contacts
The Blueshirt Group
Bob Jones, 212-871-5570, bob@blueshirtgroup.com
Chris Danne, 415-217-5865, chris@blueshirtgroup.com
credit suisse fulgent genetics healthcare conference
The Conversation (0)

Go Deeper

AI Powered
Life Science Outlook: World Edition

Life Science Outlook: World Edition

Senior woman doing exercises alongside closeup of DNA.

5 US Longevity and Anti-aging Stocks to Watch

Latest News

Outlook Reports world

Resource
  • Precious Metals
    • Gold
    • Silver
  • Battery Metals
    • Lithium
    • Cobalt
    • Graphite
  • Energy
    • Uranium
    • Oil and Gas
  • Base Metals
    • Copper
    • Nickel
    • Zinc
  • Critical Metals
    • Rare Earths
  • Industrial Metals
  • Agriculture
Tech
    • Artificial Intelligence
    • Cybersecurity
    • Gaming
    • Cleantech
    • Emerging Tech
Life Science
    • Biotech
    • Cannabis
    • Psychedelics
    • Pharmaceuticals

Featured Biotech Investing Stocks

More featured stocks

Browse Companies

Resource
  • Precious Metals
  • Battery Metals
  • Energy
  • Base Metals
  • Critical Metals
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES